Metronomic Chemotherapy: A Novel Approach in Cancer Treatment.

backgroundSystemic chemotherapy remains a cornerstone of cancer treatment, traditionally relying on maximum tolerable dosing (MTD) of cytotoxic agents to achieve remission. While MTD-based regimens have successfully treated certain malignancies such as pediatric acute lymphoblastic leukemia, their toxicity to healthy cells poses  significant health risks and limitations. Metronomic chemotherapy (MCT), characterized by the frequent administration of low-dose chemotherapeutics without prolonged breaks, has emerged as a promising alternative with distinct antiangiogenic, immunomodulatory, and tumor dormancy-inducing properties.

methodsThis review critically examines current literature on MCT, including preclinical and clinical studies, to assess its therapeutic efficacy, safety profile, and integration into standard cancer care. Emphasis is placed on evaluating combination therapies, patient selection criteria, resistance mechanisms, and nanoformulation advancements. The review also explores how MCT compares to other treatment modalities, such as immunotherapy.

resultsFindings suggest that MCT offers significant advantages over conventional MTD regimens, including reduced toxicity, improved patient tolerance, and enhanced modulation of the tumor microenvironment. Studies show promising outcomes in various cancer types, particularly when MCT is combined with other therapeutic approaches. Nanoformulations further enhance drug delivery and effectiveness, while ongoing clinical trials continue to validate its role in cancer management.

conclusionMetronomic chemotherapy presents a novel and effective strategy in oncology, with the potential to overcome limitations of traditional chemotherapy. By consolidating current evidence and clinical insights, this review supports the broader adoption of MCT and offers recommendations for optimizing its use in future cancer treatment protocols.